UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934
Date of Report (Date of earliest reported): November 10, 2016
COLLEGIUM PHARMACEUTICAL, INC.
(Exact Name of Registrant as Specified in Charter)
Virginia | | 001-37372 | | 03-0416362 |
(State or Other Jurisdiction
of Incorporation or Organization) | | (Commission File Number) | | (IRS Employer Identification
No.) |
780 Dedham Street
Suite 800
Canton, MA 02021
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (781) 713-3699
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On November 10, 2016, Collegium Pharmaceutical, Inc. issued a press release announcing its financial results for the quarterly period ended September 30, 2016. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is being furnished, not filed, under Item 2.02 of this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No. | | Description |
99.1 | | Press Release dated November 10, 2016. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| COLLEGIUM PHARMACEUTICAL, INC. |
| |
| |
Date: November 10, 2016 | By: | /s/ Paul Brannelly |
| | Name: | Paul Brannelly |
| | Title: | Executive Vice President and Chief |
| | | Financial Officer |
3
EXHIBIT INDEX
Exhibit No. | | Description |
99.1 | | Press Release dated November 10, 2016. |
4
